Serum Sema7A is increased in patients with acute aortic dissection.

IF 3.9 3区医学 Q1 PATHOLOGY Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-09-12 DOI:10.1080/14737159.2023.2254693

Xing Lyu, Xin Liu, Hui Gong, Yang Liu, Zhifang Zhou, Min Hu, Xiangyu Zhang

{"title":"Serum Sema7A is increased in patients with acute aortic dissection.","authors":"Xing Lyu, Xin Liu, Hui Gong, Yang Liu, Zhifang Zhou, Min Hu, Xiangyu Zhang","doi":"10.1080/14737159.2023.2254693","DOIUrl":null,"url":null,"abstract":"Background: To observe the level of serum Sema7A in acute aortic dissection (AAD) and its diagnostic value for AAD.Research design and methods: Patients with sudden chest pain including AAD, acute myocardial infarction (AMI) or pulmonary embolism (PE) were enrolled. Patients without chest pain or cardiovascular diseases were included as the controls. Serum Sema7A and plasma D-dimer were detected and compared in each group.Results: 85 AAD patients, 55 AMI patients, 15 PE patients, and 30 controls were enrolled. The concentration of Serum Sema7A in the AAD group was significantly higher than that in the control, AMI and PE group. Serum Sema7A was positively correlated with D-dimer. In AAD patients who underwent invasive intervention therapy, serum Sema7A levels were significantly decreased after the intervention. Serum Sema7A was an independent risk factor for the presence of AAD. The areas under the ROC curve of Sema7A and D-dimer for differential diagnosis of AAD from other chest pain disorders were 0.842 (0.776, 0.909) and 0.788 (0.714, 0.862), respectively.Conclusions: Sema7A is highly expressed in patients with AAD. Sema7A might be a valuable biomarker for the early diagnosis of AAD and has the potential to differentiate AAD from AMI and PE.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2023.2254693","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To observe the level of serum Sema7A in acute aortic dissection (AAD) and its diagnostic value for AAD.

Research design and methods: Patients with sudden chest pain including AAD, acute myocardial infarction (AMI) or pulmonary embolism (PE) were enrolled. Patients without chest pain or cardiovascular diseases were included as the controls. Serum Sema7A and plasma D-dimer were detected and compared in each group.

Results: 85 AAD patients, 55 AMI patients, 15 PE patients, and 30 controls were enrolled. The concentration of Serum Sema7A in the AAD group was significantly higher than that in the control, AMI and PE group. Serum Sema7A was positively correlated with D-dimer. In AAD patients who underwent invasive intervention therapy, serum Sema7A levels were significantly decreased after the intervention. Serum Sema7A was an independent risk factor for the presence of AAD. The areas under the ROC curve of Sema7A and D-dimer for differential diagnosis of AAD from other chest pain disorders were 0.842 (0.776, 0.909) and 0.788 (0.714, 0.862), respectively.

Conclusions: Sema7A is highly expressed in patients with AAD. Sema7A might be a valuable biomarker for the early diagnosis of AAD and has the potential to differentiate AAD from AMI and PE.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

急性主动脉夹层患者血清Sema7A升高。

背景：观察血清Sema7A在急性主动脉夹层（AAD）中的水平及其对AAD的诊断价值。研究设计和方法：选择急性主动脉夹层、急性心肌梗死（AMI）或肺栓塞（PE）等突发胸痛患者。没有胸痛或心血管疾病的患者被纳入对照组。检测各组血清Sema7A和血浆D-二聚体，并进行比较。结果：纳入AAD患者85例，AMI患者55例，PE患者15例，对照组30例。AAD组血清Sema7A浓度明显高于对照组、AMI组和PE组。血清Sema7A与D-二聚体呈正相关。在接受侵入性干预治疗的AAD患者中，干预后血清Sema7A水平显著降低。血清Sema7A是AAD存在的独立危险因素。Sema7A和D-二聚体的ROC曲线下面积分别为0.842（0.776，0.909）和0.788（0.714，0.862）。结论：Sema7A在AAD患者中高度表达。Sema7A可能是AAD早期诊断的有价值的生物标志物，并有可能将AAD与AMI和PE区分开来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Molecular Diagnostics 医学-病理学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy. Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.